E-GEOD-43024 - Transcriptional profiles of Campylobacter jejuni NCTC 11168 to 0.125mg/L erythromycin treatment
Released on 10 October 2013, last updated on 2 June 2014
Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying Campylobacter’s immediate response to Ery treatment. The design utilized an available two color microarray slide for the entire transcriptome of Campylobacter jejuni wild type strain NCTC 11168. One hybridizations were performed: sham-treated NCTC 11168 v.s. sub-lethal dose erythromycin treated NCTC 11168. Samples were independently grown and harvested. There were three biological replicates of each sample.
transcription profiling by array
Qijing Zhang, Qingqing Xia, Zuowei Wu
Adaptive mechanisms of Campylobacter jejuni to erythromycin treatment. Xia Q, Muraoka WT, Shen Z, Sahin O, Wang H, Wu Z, Liu P, Zhang Q. , Europe PMC 23767761